{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T06:27:21Z","timestamp":1794378441990,"version":"4.9.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,14]],"date-time":"2020-12-14T00:00:00Z","timestamp":1607904000000},"content-version":"vor","delay-in-days":13,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015516","name":"Revance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015516","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016348","name":"Kyowa Kirin Pharmaceutical Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007771","name":"\u015al\u0105ski Uniwersytet Medyczny","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007771","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009655","name":"Sunovion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013301","name":"Parkinson&apos;s Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013301","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014425","name":"Acorda Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014425","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005725","name":"CHDI Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.parkreldis.2020.10.029","type":"journal-article","created":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T21:22:24Z","timestamp":1602883344000},"page":"144-150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["A 12-month, dose-level blinded safety and efficacy study of levodopa inhalation powder (CVT-301, Inbrija) in patients with Parkinson's disease"],"prefix":"10.1016","volume":"81","author":[{"given":"Eric S.","family":"Farbman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl H.","family":"Waters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"LeWitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Rudzi\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Klingler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Hauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.parkreldis.2020.10.029_bib1","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1056\/NEJMct0800326","article-title":"Levodopa for the treatment of Parkinson's disease","volume":"359","author":"Lewitt","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.parkreldis.2020.10.029_bib2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00002826-198403000-00002","article-title":"Pharmacokinetics of levodopa","volume":"7","author":"Nutt","year":"1984","journal-title":"Clin. Neuropharmacol."},{"issue":"3","key":"10.1016\/j.parkreldis.2020.10.029_bib3","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/mds.1090","article-title":"Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature","volume":"16","author":"Ahlskog","year":"2001","journal-title":"Mov. Disord."},{"issue":"360","key":"10.1016\/j.parkreldis.2020.10.029_bib4","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad8858","article-title":"Preclinical and clinical assessment of inhaled levodopa for OFF episodes in Parkinson's disease","volume":"8","author":"Lipp","year":"2016","journal-title":"Sci. Transl. Med."},{"issue":"15","key":"10.1016\/j.parkreldis.2020.10.029_bib5","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1002\/mds.22340","article-title":"Movement disorder society UPRS revision task force, movement disorder society-sponsored revision of the unified Parkinson's disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov. Disord."},{"issue":"2","key":"10.1016\/j.parkreldis.2020.10.029_bib6","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S1474-4422(18)30405-8","article-title":"SPAN-PD Study Investigators, Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial","volume":"18","author":"LeWitt","year":"2019","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.parkreldis.2020.10.029_bib7","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.parkreldis.2019.12.012","article-title":"Inhaled levodopa in Parkinson's disease patients with OFF periods: a randomized 12-month pulmonary safety study","volume":"71","author":"Grosset","year":"2020","journal-title":"Park. Relat. Disord."},{"issue":"6","key":"10.1016\/j.parkreldis.2020.10.029_bib8","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1136\/jnnp.51.6.745","article-title":"The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease","volume":"51","author":"Gibb","year":"1988","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"4","key":"10.1016\/j.parkreldis.2020.10.029_bib9","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/archneur.1969.00480160015001","article-title":"Treatment of parkinsonism with levodopa","volume":"21","author":"Yahr","year":"1969","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.parkreldis.2020.10.029_bib10","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.parkreldis.2019.03.026","article-title":"Orally inhaled levodopa (CVT-301) for early morning OFF periods in Parkinson's disease","volume":"64","author":"Hauser","year":"2019","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2020.10.029_bib11","series-title":"Physiology","author":"Costanza","year":"2006"},{"issue":"6","key":"10.1016\/j.parkreldis.2020.10.029_bib12","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1183\/09031936.00080312","article-title":"Lung Function Initiative, Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations","volume":"40","author":"Quanjer","year":"2012","journal-title":"Eur. Respir. J."},{"issue":"10","key":"10.1016\/j.parkreldis.2020.10.029_bib13","doi-asserted-by":"crossref","first-page":"863","DOI":"10.3949\/ccjm.70.10.866","article-title":"Interpreting pulmonary function tests: recognize the pattern, and the diagnosis will follow","volume":"70","author":"Al-Ashkar","year":"2003","journal-title":"Cleve. Clin. J. Med."},{"issue":"2","key":"10.1016\/j.parkreldis.2020.10.029_bib14","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/00002826-200003000-00003","article-title":"A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia","volume":"23","author":"Hauser","year":"2000","journal-title":"Clin. Neuropharmacol."},{"issue":"11","key":"10.1016\/j.parkreldis.2020.10.029_bib15","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1136\/jnnp.2006.111161","article-title":"The 39 item Parkinson's disease questionnaire (PDQ-39) revisited: implications for evidence based medicine","volume":"78","author":"Hagell","year":"2007","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.parkreldis.2020.10.029_bib16","series-title":"Schwab and England Activities of Daily Living Scale, Encyclopedia of Movement Disorders","first-page":"99","author":"Siderowf","year":"2010"},{"key":"10.1016\/j.parkreldis.2020.10.029_bib17","first-page":"153","article-title":"Members of the UPDRS development committee. Unified Parkinson's disease rating scale","volume":"vol. 2","author":"Fahn","year":"1987"},{"issue":"10","key":"10.1016\/j.parkreldis.2020.10.029_bib18","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1002\/mds.22571","article-title":"Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease","volume":"24","author":"Weintraub","year":"2009","journal-title":"Mov. Disord."},{"issue":"6","key":"10.1016\/j.parkreldis.2020.10.029_bib19","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/sleep\/14.6.540","article-title":"A new method for measuring daytime sleepiness: the Epworth sleepiness scale","volume":"14","author":"Johns","year":"1991","journal-title":"Sleep"},{"issue":"12","key":"10.1016\/j.parkreldis.2020.10.029_bib20","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults","volume":"168","author":"Posner","year":"2011","journal-title":"Am. J. Psychiatr."},{"issue":"3","key":"10.1016\/j.parkreldis.2020.10.029_bib21","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1164\/rccm.201310-1863PP","article-title":"Minimal clinically important differences in pharmacological trials","volume":"189","author":"Jones","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.parkreldis.2020.10.029_bib22","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3109\/15412555.2014.898051","article-title":"Minimum clinically important difference in diffusing capacity of the lungs for carbon monoxide among patients with severe and very severe chronic obstructive pulmonary disease","volume":"12","author":"Horita","year":"2015","journal-title":"COPD"},{"issue":"3","key":"10.1016\/j.parkreldis.2020.10.029_bib23","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/mds.27932","article-title":"Brainstem ventilatory dysfunction: a plausible mechanism for dyspnea in Parkinson's Disease?","volume":"35","author":"Vijayan","year":"2020","journal-title":"Mov. Disord."}],"container-title":["Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802020308221?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802020308221?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T19:14:21Z","timestamp":1762370061000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802020308221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":23,"alternative-id":["S1353802020308221"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2020.10.029","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A 12-month, dose-level blinded safety and efficacy study of levodopa inhalation powder (CVT-301, Inbrija) in patients with Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2020.10.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}